Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Press Releases

Press Releases

  • Jan 24, 2019
    Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares
    CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten
  • Jan 23, 2019
    Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares
    CAMBRIDGE, Mass. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of




  • Events and Presentation